ClearPoint Neuro Inc vs 3M Company — how do they compare? ClearPoint Neuro Inc trades at $14.92 (market cap $444.14M), while 3M Company trades at $183.06 (market cap $93.88B). The key difference: 3M Company is far larger — about 211.4× ClearPoint Neuro Inc's market cap, and 3M Company pays a 1.71% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | MMM | |
|---|---|---|
Market Cap | $444.14M | $93.88B |
Sector | Health | Industrials |
52-Week High | $29.60 | $183.13 |
52-Week Low | $8.66 | $141.10 |
Enterprise Value | $478.72M | $103.10B |
Dividend Yield | — | 1.71% |
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $14.21, up 6.12% today, amid mixed technical signals and challenging fundamentals. The company reported Q2 2026 revenue growth but missed earnings expectations with a loss of $0.38 per share, continuing a trend of negative profitability. Despite 100% analyst buy ratings, financial metrics show significant losses with a net income margin of -81.76% and negative cash flow from operations of $30 million projected for 2026.
The investment case hinges on regulatory progress and partnership developments in neurotechnology, but substantial execution risks and persistent losses present headwinds. While analyst consensus remains bullish on long-term potential, current financial performance suggests cautious optimism is warranted until profitability improves.
3M (MMM) trades at $182.89, up 1.21% today, with a bullish technical signal from moving averages and strong support at $180. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $2.40 exceeding the $2.25 estimate, and raised its full-year guidance. Revenue for 2025 was $24.95 billion, with a net income margin of 11.9% and a high return on equity of 82.77%. Recent news highlights strength in the Safety & Industrial segment and a partnership with Microsoft on EBO technology.
The outlook is positive due to operational improvements and innovation, but risks include litigation liabilities and macroeconomic pressures. Analysts are mixed with a consensus price target of $173.00, below the current price, suggesting cautious optimism. The stock's valuation metrics, such as a P/E of 32.49, indicate it may be fully priced, requiring careful monitoring of execution against raised guidance.
Trailing returns across standard periods
Latest headlines on both assets
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →